VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

B. melitensis strain VTRM1
Vaccine Information
  • Vaccine Name: B. melitensis strain VTRM1
  • Target Pathogen: Brucella spp.
  • Target Disease: Brucellosis
  • Vaccine Ontology ID: VO_0000300
  • Type: attenuated live vaccine
  • Preparation: VTRM1 was obtained from B. melitensis 16M by allelic exchange of the rfbU gene encoding mannosyltransferase with a Tn5-disrupted rfbU gene (Winter et al., 1996).
  • Virulence: VTRM1, like RB51, is a stable rough form of B. melitensis that does not revert during passage in mice (Winter et al., 1996).
  • Description: Vaccination with the rough strain VTRM1 induces protection against virulent strains of B. abortus (2308), B melitensis (16M), B. suis biovar 1 (750), B. suis biovar 4 (2579), and B. ovis (Winter et al., 1996).
Host Response

Mouse Response

  • Host Strain: VTRM1
  • Vaccination Protocol: Five groups of mice, (eight to nine weeks old), were vaccinated with the following live organism vaccines. These included: VTRM1, VTRS1, and Rev 1 (5 x 10^4 CFU); strain 19 (S19) (5 x 10^3 CFU); and RB51 (3 x 10^8 CFU). Each vaccine was delivered intravenously except RB51 which was administered intraperitoneally. All vaccines except RB51 were obtained directly from frozen stock cultures. Large doses of RB51 were required, therefore stock cultures were inoculated onto plates. After three days of culture and growth after 3 days was diluted to the appropriate concentration (Winter et al., 1996).
  • Challenge Protocol: Eight weeks after the initial vaccination, mice were injected IV with 5x10^4 CFU of Brucella. The time interval between IV injection and euthanasia was two weeks for all Brucella strains with the exception of B abortus 8-954 and 2-1230; for these strains, a one-week time interval was chosen. Mice were euthanized by CO2 asphyxiation. Individual spleens were homogenized, the homogenate diluted serially, and plated on Schaedler blood agar. B abortus, B melitensis, or B suis colonies were counted after three days of incubation; B. ovis colonies were counted after four to five days of incubation at 37 C under 10% CO2 (Winter et al., 1996).
  • Efficacy: Strains VTRM1 and VTRS1 were effective in inducing protection against virulent strains of heterologous, and homologous, Brucella spp. Vaccination with either strain conferred substantial protection against exposure to virulent laboratory strains of B melitensis, B abortus, and B suis of biovars 1 and 4. VTRM1 provided protection against B. ovis (Winter et al., 1996).
References
Winter et al., 1996: Winter AJ, Schurig GG, Boyle SM, Sriranganathan N, Bevins JS, Enright FM, Elzer PH, Kopec JD. Protection of BALB/c mice against homologous and heterologous species of Brucella by rough strain vaccines derived from Brucella melitensis and Brucella suis biovar 4. American journal of veterinary research. 1996 May; 57(5); 677-83. [PubMed: 8723881].